{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:08:38Z","timestamp":1760299718441,"version":"3.37.3"},"reference-count":49,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T00:00:00Z","timestamp":1508371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>During the last 10\u00a0years, clinical trials formally demonstrated that about 50% of patients with chronic phase (<jats:styled-content style=\"fixed-case\">CP<\/jats:styled-content>) chronic myeloid leukaemia (<jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content>) who achieve and maintain deep molecular responses for a prolonged period of time during treatment with imatinib or new generation tyrosine kinase inhibitors (<jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content>s) may successfully stop their anti\u2010leukaemic therapy. Based on the accumulated knowledge from abundant clinical trial experience, <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content> discontinuation is becoming an important goal to achieve and is about to enter clinical practice. This review focuses on relapse definition, laboratory tests to identify relapse and relapse management after <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content> discontinuation.<\/jats:p>","DOI":"10.1111\/bjh.14973","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T10:46:53Z","timestamp":1508410013000},"page":"24-32","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy"],"prefix":"10.1111","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5379-7461","authenticated-orcid":false,"given":"Delphine","family":"Rea","sequence":"first","affiliation":[{"name":"Service d'h\u00e9matologie Adulte Unit\u00e9 INSERM UMR\u20101160 and France Intergroupe des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques (Fi\u2010LMC) H\u00f4pital Saint\u2010Louis Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois\u2010Xavier","family":"Mahon","sequence":"additional","affiliation":[{"name":"Unicancer Center Institut Bergoni\u00e9 and France Intergroupe des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques (Fi\u2010LMC) Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,10,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00072-1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-393041"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2839-z"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-327437"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30066-2"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35721"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.29"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.095158"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2914"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23560"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500407996"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7757"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.319"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-326843"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.9020"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.63"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694265"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273979"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.360"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00196-9"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1816"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3320"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1043548"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23427"},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.30885","article-title":"Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia","author":"Legros L.","year":"2017","journal-title":"Cancer"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.1.214"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_9_32_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.787.787","article-title":"Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro\u2010Ski trial","volume":"128","author":"Mahon F.X.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24120"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4718"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404983"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08939.x"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2317-z"},{"key":"e_1_2_9_38_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.789.789","article-title":"No differences in molecular relapse\u2010free survival after stopping imatinib treatment of chronic myeloid leukemia between patients with prior 4.5 log reduction (MR4.5) but detectable and patients with undetectable disease in the EURO\u2010SKI trial","volume":"128","author":"Pfirrmann M.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1701"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2318-y"},{"key":"e_1_2_9_41_1","article-title":"Treatment\u2010free remission in patients with chronic myeloid leukemia","author":"Rea D.","year":"2017","journal-title":"International Journal of Hematology"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-742205"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.165001"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5797"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-617993"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.115"},{"key":"e_1_2_9_48_1","article-title":"Treatment\u2010free remission (TFR) in patients with chronic phase chronic myeloid leukemia (CML\u2010CP) and in stable deep molecular response (DMR) to dasatinib \u2013 the Dasfree study","volume":"128","author":"Shah N.P.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_9_49_1","first-page":"1","article-title":"Patient perceptions of treatment\u2010free remission in chronic myeloid leukemia","volume":"15","author":"Villemagne Sanchez L.A.","year":"2017","journal-title":"Leukemia & Lymphoma"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701729"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14973","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T19:38:34Z","timestamp":1696016314000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,19]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/bjh.14973"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14973","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2017,10,19]]},"assertion":[{"value":"2017-10-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}